Any content you receive is for information purposes only. Always conduct your own research. *Sponsored
Onconetix, Inc. (Nasdaq: ONCO) Just Hit The Top Of Paul Prescott's Watchlist This Morning—Monday, July 6, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Pull Up ONCO While It’s Still Early…
July 6, 2026 Dear Reader, If you read one thing from us today—Monday, July 6, 2026—make it this. Onconetix, Inc. (Nasdaq: ONCO) already tapped $1.17 according to Robinhood, marking an approximate 23% move off of its previous day’s $.95 range. This morning we put ONCO at the top of our watchlist, and the reason holds all session long: this is a company running two stories at once. Track one is diagnostics. Proclarix, its CE-IVD certified blood-based test for prostate cancer, is in a multi-center U.S. validation study with Labcorp designed to enroll up to 500 men, while its European commercial footprint expands. Track two is the transformation. Onconetix signed a definitive agreement earlier this year to acquire 100% of Realbotix LLC, an American designer and manufacturer of humanoid robots built for direct human interaction, with closing anticipated in the second half of 2026, subject to shareholder approval and regulatory clearances. Wrapped around both tracks is the number that makes this name different: fewer than 1.2M shares listed as available to the public. Structures this compressed have responded to headlines before, including an approximate 56% single-session move in April reported by Benzinga and an approximate 34% move inside of just 8 sessions, from around $.88 on June 18 to $1.18 on June 30, according to Barchart. 
And now, ONCO appears to be flying under the radar while it’s currently trending in the $1 range. Meanwhile, the legacy business is moving too. Onconetix's Swiss subsidiary, Proteomedix AG, has initiated a multi-center U.S. validation study for its Proclarix prostate cancer blood test in collaboration with Labcorp, designed to enroll up to 500 men. Two potential catalysts, two very different industries, and one very small share count. These are just some of the reasons why ONCO is on our radar. Leadership has been rebuilt around the transaction as well. In March, the board appointed David White as Chief Executive Officer, a 30-year operator with prior CEO, CFO, and COO roles across transportation, healthcare, and manufacturing, and added Sammy Dorf, co-founder of Verano Holdings, to the board and its Audit Committee. Management has framed its mandate plainly: complete the Realbotix transaction with discipline and position the combined company for durable growth. About Onconetix (Nasdaq: ONCO) Onconetix, Inc. is a commercial-stage biotechnology company headquartered in Cincinnati, Ohio. Its principal asset today is Proclarix, a CE-IVD certified blood-based diagnostic used alongside PSA testing to identify clinically significant prostate cancer. Proclarix was developed by Proteomedix AG, the company's fully owned Swiss subsidiary, and is approved for sale in the European Union under the IVDR. In the United States, the company anticipates Proclarix will be marketed as a lab developed test through its license agreement with Labcorp, one of the largest clinical laboratory networks in the world. European commercial activity is expanding as well: a patient organization in the United Kingdom now offers Proclarix within a real-world screening initiative, with close to 100 tests carried out under that program in the first quarter alone, and a collaboration partner has been identified in Turkey. The operating picture changes considerably with the pending Realbotix transaction. On February 12, 2026, Onconetix entered a definitive share exchange agreement to acquire 100% of the issued and outstanding equity interests of Realbotix LLC from Realbotix Corp. Realbotix designs, builds, and manufactures customizable, life-sized humanoid robots in the United States. Its patented technologies enable lifelike expressions, vision, and social interaction, and its robots serve customer-facing roles across healthcare, education, hospitality, and entertainment. At CES 2026, Realbotix demonstrated two fully autonomous humanoid robots holding an unscripted conversation with each other across multiple languages, running entirely on-device with proprietary models. If the transaction closes as anticipated, public market participants would gain Nasdaq access to an American humanoid robotics manufacturer with commercial units already in the field. Realbotix has also been widening the ways customers reach its technology. Its Ask Aria chatbot lets the public hold emotionally intelligent voice conversations with a digital version of its flagship robot, and a partnership with The FUTR Corporation is intended to give FUTR's AI agents a physical, interactive form through Realbotix hardware. The commercial thesis is straightforward: as enterprises look for embodied interfaces for their AI systems, Realbotix already builds the body. The Market Behind The Machines
Humanoid robotics has moved from research curiosity to a big forecast at the largest firms in the market. Goldman Sachs Research projects the total addressable market for humanoid robots will reach $38B by 2035, a sixfold increase from its prior estimate, with shipments of roughly 1.4M units. The firm attributes the revision primarily to faster-than-expected AI progress and a 40% reduction in the cost of materials. Morgan Stanley goes further out on the curve, forecasting a $5T humanoid robotics market by 2050. What separates Realbotix from the industrial names in this sector is its focus on human interaction rather than warehouse labor. While much of the field chases factory tasks, Realbotix has concentrated on the social layer: robots that recognize returning users, recall prior conversations, and maintain eye contact through its patented Vinci AI vision system. Its first enterprise client is Ericsson, and its AI-agnostic architecture allows the robots to integrate with a variety of AI systems, cloud platforms, and network environments rather than depending on a single provider. The diagnostics side addresses a different structural problem. Prostate cancer is the most frequently diagnosed male cancer in most countries globally, and overdiagnosis and unnecessary biopsies remain a persistent cost burden on healthcare systems. New clinical data published this year reinforce Proclarix's performance in reducing both, which is the commercial argument behind the Labcorp relationship in the U.S. market. For a company this size, holding assets in two sectors with independent demand drivers is unusual, and it gives readers two separate news streams to monitor rather than one. Goldman's analysts also note that most of the hardware for humanoid robots, from cameras and motors to force sensors and batteries, is already available or close to maturity for commercial purposes. That matters for a manufacturer like Realbotix, which is scaling production now rather than waiting on component breakthroughs. The bottleneck in this sector is shifting from whether the machines can be built to who can place them in front of paying customers, and Realbotix has been doing exactly that with Ericsson, a New York school district, and 19 robot deliveries scheduled across a single spring quarter. The Developments Driving The Story
- June 24, 2026: Onconetix highlighted Realbotix's launch of Optio, its AI-powered teacher's assistant, in a pilot program at Salamanca City Central School District in New York, alongside deployment of an M-Series humanoid robot, with the pilot planned to expand to approximately 500 high school students in Fall 2026.
- May 13, 2026: The company reported first-quarter progress at Proteomedix, including two new peer-reviewed publications, initiation of the multi-center PRIME validation study with Labcorp designed to include up to 500 men (first participants enrolled), and continued European commercial expansion.
- April 9, 2026: Onconetix highlighted the delivery of the first Vinci-equipped humanoid robot to Ericsson. Vinci's in-eye cameras let the robot recognize people it has met, recall prior conversations, and track engagement.
- April 2, 2026: Realbotix announced expected delivery of 19 previously ordered robots across March, April, and May 2026 as it scales production capacity.
- March 31, 2026: The company appointed David White as Chief Executive Officer and added Sammy Dorf, co-founder of Verano Holdings, to its Board of Directors and Audit Committee.
- March 25, 2026: A Realbotix humanoid robot, purchased by Ericsson as the company's first enterprise robotics client, was featured as a live connected endpoint in Ericsson's world-first pre-standard 6G over-the-air trial at its U.S. headquarters in Plano, Texas.
- February 12, 2026: Onconetix entered a definitive share exchange agreement to acquire 100% of Realbotix LLC in an all-share transaction, with the combined company expected to continue on Nasdaq following a closing anticipated in the second half of 2026.
7 Reasons Why (ONCO) Just Secured The Top Spot On Today's Watchlist—Monday, July 6, 2026… 1. Massive Market Outlook: ONCO’s pending Realbotix acquisition would connect it to humanoid robotics, a sector Goldman Sachs Research projects could reach $38B by 2035, while Morgan Stanley forecasts a $5T market by 2050.
2. Small Float: With less than 1.2M shares listed as available to the public, ONCO’s small float could have the potential to witness big moves if demand begins to shift. 3. Recent Momentum: ONCO made an approximate 56% single-session move in April following news tied to Realbotix and recently made approximately 34% over eight sessions in June, according to Benzinga and Barchart. 4. Humanoid Platform: ONCO has signed a definitive agreement to acquire Realbotix, positioning the company to combine its diagnostics business with a humanoid robotics platform, subject to shareholder approval and regulatory clearances. 5. Layered Story: ONCO brings together two separate areas to monitor—a pending humanoid robotics transaction and ongoing advancement of its Proclarix prostate cancer diagnostic program. 6. Clinical Advancement: ONCO continues advancing its legacy diagnostics business through a multi-center U.S. validation study with Labcorp while expanding Proclarix's commercial presence in Europe. 7. C-Suite Change: ONCO strengthened its leadership team earlier this year by appointing a new Chief Executive Officer and adding Verano Holdings co-founder Sammy Dorf to its Board of Directors and Audit Committee. Pull Up ONCO While It’s Still Early…
Street Ideas is watching ONCO because this is not a one-headline setup. It is a developing story built around a pending Realbotix acquisition, Proclarix progress, leadership additions, and an unusually small share structure. We have all eyes on ONCO this morning. Pull up ONCO while it’s still early. Sincerely, Paul Prescott Co-Founder & Managing Editor Street Ideas Newsletter |
